Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Public Parks in the USA - 25 Home Improvement Styles: Decision in favor of Your #1
- 3Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- 4US healthcare spending soars to over $5 trillion in 2024
- 5James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead
- Supportive Tips On Home loans For First-Time Home Purchasers
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- Figure out How to Stay away from Normal Handshaking Missteps
- Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- Germany sees third consecutive diesel price record after rule change
- Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- Picking the Right Home Machines: A Commonsense Aide
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
